- Home
- KOD vs PROC Comparison
KOD vs PROC Comparison
Compare KOD & PROC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KOD
- PROC
- Stock Information
- Founded
- KOD 2009
- PROC 1976
- Country
- KOD United States
- PROC Luxembourg
- Employees
- KOD N/A
- PROC N/A
- Industry
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- PROC Biotechnology: Pharmaceutical Preparations
- Sector
- KOD Health Care
- PROC Health Care
- Exchange
- KOD Nasdaq
- PROC Nasdaq
- Market Cap
- KOD 186.3M
- PROC 203.1M
- IPO Year
- KOD 2018
- PROC N/A
- Fundamental
- Price
- KOD $5.90
- PROC $1.10
- Analyst Decision
- KOD Hold
- PROC
- Analyst Count
- KOD 5
- PROC 0
- Target Price
- KOD $3.50
- PROC N/A
- AVG Volume (30 Days)
- KOD 418.9K
- PROC 68.7K
- Earning Date
- KOD 11-26-2024
- PROC 11-26-2024
- Dividend Yield
- KOD N/A
- PROC N/A
- EPS Growth
- KOD N/A
- PROC N/A
- EPS
- KOD N/A
- PROC 0.52
- Revenue
- KOD N/A
- PROC $414,096,000.00
- Revenue This Year
- KOD N/A
- PROC $5.54
- Revenue Next Year
- KOD N/A
- PROC $8.54
- P/E Ratio
- KOD N/A
- PROC $1.11
- Revenue Growth
- KOD N/A
- PROC N/A
- 52 Week Low
- KOD $2.19
- PROC $0.50
- 52 Week High
- KOD $7.77
- PROC $4.95
- Technical
- Relative Strength Index (RSI)
- KOD 80.20
- PROC 41.91
- Support Level
- KOD $5.08
- PROC $0.50
- Resistance Level
- KOD $6.00
- PROC $1.76
- Average True Range (ATR)
- KOD 0.38
- PROC 0.18
- MACD
- KOD 0.06
- PROC -0.06
- Stochastic Oscillator
- KOD 94.14
- PROC 44.44
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is KSI-301, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD.
About PROC Procaps Group S.A.
Procaps Group SA is a developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. It develops, manufactures, and markets over-the-counter (OTC) and prescription drugs, nutritional supplements, and high-potency clinical solutions. The company's segment includes NextGel; Procaps Colombia; CAN; CASAND and Diabetrics. It generates maximum revenue from the Procaps Colombia segment.